Skip to content
BY-NC-ND 3.0 license Open Access Published by De Gruyter October 17, 2015

Effect of gel properties on transdermal iontophoretic delivery of diclofenac sodium

S. Arunkumar, H.N. Shivakumar, B.G. Desai and Purnima Ashok
From the journal e-Polymers

Abstract

The aim of the study was to develop hydrogels and investigate the suitability for transdermal delivery of diclofenac sodium (DS) using constant voltage iontophoresis (CVI). Four batches of hydrogels of DS were developed using hydroxylethyl cellulose (HEC) as matrix material and terpenes as penetration enhancers. The hydrogels displayed a viscosity of ~1500 cps at a shear rate of 250 s-1 that was unlikely to change on minute shift in pH or temperature so that the iontophoretic transport would be unaffected. Moreover, the hydrogels were found to possess adequate conductivity at pH 7.4 to enable iontophoretic delivery of DS. In vitro studies indicated that passive transport of DS across porcine skin from hydrogels was comparable (p>0.05) to aqueous solution. The lead hydrogel (F1), containing geraniol was found to enhance the iontophoretic flux of DS by 5.16 fold at 1.5 V compared to passive control. In vivo studies in rats indicated that CVI on application of F1 significantly suppressed (p<0.001) carrageenan induced edema compared to passive treatment throughout the study.

1 Introduction

People throughout the world are known to suffer from pain and disability due to various musculoskeletal (MSK) disorders. MSK disorders account for nearly 3.4% and 1.7% of the total global disease burden in the developed and developing countries respectively (1). Currently, the treatment for MSK disorders involves oral or parentral administration of steroids or non steroidal anti-inflammatory drugs (NSAIDs). NSAIDs are known to provide symptomatic relief from pain, allow quicker recovery and return to normal activity (2). Diclofenac is a NSAID that is commonly used in chronic pain management associated with various MSK disorders (3). Though the drug relieves pain by reducing prostaglandin synthesis, diclofenac undergoes extensive hepatic first pass metabolism that invariably limits the oral bioavailability to 50–60%. Therefore, the drug needs to be frequently administered at a daily dose of 150 mg in three divided doses (3). Owing to the non-selective cyclooxygenase inhibition and the frequent dosing, oral diclofenac is frequently associated with severe gastrointestinal side effects, which invariably limits its long-term use. Transdermal administration is likely to overcome hepatic first pass metabolism, improve bioavailability, allow dose reduction, reduce systemic exposure and thereby the dose-dependent adverse effects and eventually improve patient compliance. Though transdermal therapy is known to overcome the gastrointestinal adverse effects of oral diclofenac, the penetration of therapeutic amounts into underlying inflamed tissues has been a big challenge (4). Considering the limitations of these products, the current work primarily aims to enhance the transdermal delivery of diclofenac sodium (DS) from hydrogels using constant voltage iontophoresis (CVI). CVI is an electrically assisted technique that can promote the transdermal transport of ionic permeants under the influence of applied low voltage (5). Though constant current iontophoresis has been used in the past to enhance the transdermal transport of DS from aqueous solutions (6–10), no attempt has been made till date to investigate the iontophoretic transport of DS from hydrogels under constant voltage. In this context, the present study aims to formulate hydrogels of DS using generally regards as safe (GRAS) listed excipients and characterize the same to assess their suitability for transdermal iontophoretic delivery.

2 Materials and methods

2.1 Materials

Diclofenac sodium was purchased from Yarrow Chemicals (Mumbai, India) Natrosol 250 M, a sample of hydroxyethyl cellulose (HEC) was donated by Ashland Chemicals Ltd (Mumbai, India). Geraniol, l-menthol, thymol and δ-carrageenan were purchased from Sigma-Aldrich (Bangalore, India). The rest of the chemicals and reagents of analytical grade were bought from S.D. Fine Chemicals (Mumbai, India). Deionized water (resistivity~18 MΩ-cm) was used for all the preparations.

2.1.1 Animals

The in vivo experimental protocol was approved by institutional Animal Ethical Committee (No.06/SAK/HNSK/01/2013). Male Wistar rats weighing 200–250 g were used for all the studies.

2.2 Determination of partition coefficient

The partition coefficient of DS was determined in phosphate buffer (PB) of pH 7.40 and n-octanol system. Aqueous solutions of DS in PB (2 mg/ml) was equilibrated with equal volume of n-octanol for 24 h with intermittent shaking after which the resultant mixture was centrifuged at 2000 rpm for 10 min to separate the two constituent phases. Later, the amount of drug in aqueous phase was determined spectrophotometrically at 276 nm (UV-1800, Shimadzu Corporation, Kyoto, Japan) on suitable dilution. The partition coefficient was determined using equation [1] after calculating the differential amount of DS partitioned into n-octanol (11).

(1)log P=logCOCPB (1)

Where, CO and CPB represent the DS concentration in organic phase and PB, respectively.

2.3 pH solubility profiling

The solubility of DS was determined spectrophotometrically at pH values of 1.2, 4.0, 5.0, 6.8 and 7.4 to establish the pH solubility profile of the drug. The fraction of DS ionized at different pH was calculated by as per Henderson-Hasselbach’s equation [2]

(2)% Ionized=1001+10pH-pKa (2)

2.4 Gel preparation

Hydrogels of DS were prepared in dual asymmetric centrifuge (DAC 150 Speed mixer, Hauschild and Co. Waterkamp, Germany) using HEC as a matrix material. Terpenes like geraniol, l-menthol and thymol were incorporated as a penetration enhancer into hydrogels F1, F2, and F3, respectively while the control gel (Fc) was devoid of any enhancer. The composition of different gel formulations are outlined in Table 1. Briefly, DS (1% w/w), terpenes (5% w/w), ethanol (40% w/w) in PB (Q.S) were taken to a mixing cup of the speed mixer and dispersed at 3000–3500 rpm and for 8 min (12). Subsequently, HEC was added to the cup and mixed for another 10 min at the same speed to obtain a clear homogeneous hydrogel free from air bubbles. The hydrogels were subjected to physicochemical characterization before further characterization.

Table 1

Composition of DS hydrogels.

IngredientsComposition (% w/w)
FCF1F2F3
DS1.001.001.001.00
Geraniol5.00
l-menthol5.00
Thymol5.00
Ethanol40.0040.0040.00
HEC2.752.752.752.75
PB (QS)a100.00100.00100.00100.00

aQS, Quantity sufficient.

2.5 pH measurements

The pH of the hydrogels were determined using an Orion pH meter (115/220 VAC, Thermo Scientific, India). The hydrogels were taken in separate glass beakers and the electrode was dipped 2–3 cm deep into the gel to measure the pH. If necessary, the gels were set to pH of 7.40±0.50 using 3 molar sodium dihydrogen phosphate or disodium hydrogen phosphate.

2.6 IR Spectrometry

Infrared spectra of DS and drug loaded hydrogel were recorded in region of 4000–400 cm-1 in an attenuated total refluctance (ATR) spectrometer (Alpha, Bruker, Billerica, MA, USA) at 20°C to identify the functional groups in DS. No special procedure was involved in sample preparation as the samples were directly exposed to the IR rays in ATR spectrometer. The spectra of the gel were compared to that of DS to establish the chemical integrity of DS in gels.

2.7 Viscosity profiling

The viscosity of DS hydrogels was determined in a modular compact rheometer (MCR-302, Anton-Paar Gmbh, Austria) using a PP50/P2 spindle. The hydrogels were loaded on to the lower peltier plate of the rheometer and the measuring head was lowered to a gap of 0.5 mm. The viscosity was recorded by varying the shear rate between 250 s-1 and 1 s-1 at a temperature of 25±0.2°C (13).

2.8 Conductivity measurement

The ability of the hydrogel to carry the electric current was assessed by measuring the conductivity (14). Prior to the measurement, conductivity meter (CD-4301, Ankom International, India) was calibrated using standard calibration solution (0.05% w/v NaCl solution) at 25±0.5°C. Subsequently, the conductance of the samples was measured at the same temperature by dipping the electrode into the beaker containing hydrogels.

2.9 Skin preparation

Porcine ears from the pigs of 6–8 months of age were procured from a nearby local slaughter house. Hairs from the surface of ears were removed using a custom made electrical trimmer while the whole skin was separated from the underlying cartilage using a surgical scalpel. The fat underlying the subcutaneous layer was carefully removed using a pair of surgical scissors. Later, the full thickness skin was washed with water before use (11).

2.10 Electrodes preparation

Most of the iontophoretic studies recommend the use of silver-silver chloride (Ag-AgCl) electrodes due to their stability and reversibility (15). Two silver wires having a diameter 0.8 mm were connected to the two terminals of a direct current source while the free ends were dipped in 0.1 N hydrochloric acid (HCl). AgCl was gradually deposited on the anode after passing the current for a period of 6 h. This Ag electrode thus coated with AgCl was used as a cathode for the iontophoresis studies while Ag wire was used as an anode.

2.10.1 In vitro passive diffusion

In vitro passive permeation studies of DS from hydrogels were conducted for a period of 8 h in a modified Franz diffusion cells (FDC) (11). The porcine skin was sandwiched between the two halves of a diffusion cell in such a way that the epidermis was facing the donor compartment. DS gels (0.5 g) were charged into the donor compartment while the receiver compartment filled with phosphate buffer saline (PBS) was maintained at 37±0.5°C and a stirring speed of 600±10 rpm in a diffusion cell apparatus. Samples (0.5 ml) from the receiver were withdrawn from sampling port of the FDC at 1, 2, 3, 4, 6 and 8 h, suitably diluted and analyzed by high performance liquid chromatography (HPLC).

2.10.2 In vitro iontophoretic permeation

The in vitro iontophoretic permeation studies of DS from hydrogels were performed under a similar set of conditions for a period of 8 h in modified FDC. However, an AgCl cathode was mounted on the donor while a pure Ag wire placed in the receiver compartment served as an anode during the iontophoretic studies. A constant voltage was applied across the electrodes during the studies and the current flowing through the circuit was constantly monitored with a digital multimeter. Samples from the receiver were withdrawn during the study, suitably diluted and analyzed by HPLC. The amount of DS diffused per unit area of the skin from the hydrogels was plotted against time and the steady state flux (Jss) was obtained from the slope of the linear portion of the plot. The enhancement ratios (ER) for the hydrogel were determined using equation [3] (11).

(3)ER=Iontophoretic fluxPassive flux (3)

The target flux (F) for DS was calculated as per equation [4] from the pharmacokinetic parameters cited in the literature (16).

(4)F=CSSClTWA (4)

where, ClT stands for total body clearance of diclofenac, which is reported to be 4.2±0.9 ml/min.kg (17). The steady state plasma concentration (Css) was assumed to be 400 ng/ml that represented half of the peak concentration achieved in blood after an oral dose of 50 mg in human volunteers (18). “W” refers to the standard body weight (~60 kg), while “A” represents the area of transdermal patch.

2.11 HPLC analysis

The samples collected at each time point during in vitro studies were analyzed in a liquid chromatographic system (LC-2010CHT, Shimadzu Corporation, Japan). The samples were analyzed using a UV detector at 276 nm at the oven temperature of 25±0.2°C (19). The mobile phase comprising of a mixture of acetonitrile:deionized water (70:30 v/v) was set to pH of 3.5 before elution of DS.

2.12 In vivo pharmacodynamics

Four groups of animals with six animals in a group were used for the pharmacodynamic studies. Prior to the start of the studies, animals were anesthetized using ketamine hydrochloride by intraperitoneal injection and clipped to a wooden board with the abdomen facing upwards. DS was allowed to passively diffuse after the application of FC and F1 hydrogels for the first and second groups of animals, respectively. CVI (1.5 V) was applied after applying hydrogel F1 to the third group while no hydrogel was applied to the positive control group.

One hour after treatment, carrageenan solution (0.05 ml of 1% solution in normal saline) was injected into the sub-plantar region of right hind paw for all the animals to induce the inflammation (20). Subsequently, the thickness of swollen paw of all the animals was measured using a digital vernier caliper (Mitutoyo, Kawasaki, Japan) at 0, 1, 3, 5 and 8 h following the injection. The percentage inhibition of paw thickness was calculated using equation [5] (21).

(5)% Inhibition=(Ct-C0)Control-(Ct-C0)Treated(Ct-C0)Control×100 (5)

where Ct and C0 represent the paw thickness at time “t” and “0” after injection.

2.13 Statistical analysis

The data was statistically compared by performing ANOVA in GraphPad Instat 5.0 demo version software (GraphPad Inc., CA, USA). The probability value of <0.05 was considered to be significant.

3 Results and discussion

Iontophoresis is found to be more effective compared to passive diffusion in delivering charged therapeutic agents to subdermal tissues as it is known to promote direct tissue penetration rather than systemic reabsorption. Moreover, iontophoresis is considered to be the right option to deliver NSAIDs as the technique is likely to ensure a quicker onset of action when compared to a passive transdermal patch (22). However, most often iontophoretic delivery is determined by gel properties like pH, viscosity, and conductivity (14).

3.1 Determination of partition coefficient

DS seems to be an ideal molecule for iontophoretic transdermal delivery by virtue of its low molecular weight (334.24 Da) and high charge to mass ratio (2.99×10-3). The experimental value of partition coefficient of DS in n-octanol-PB system was found to be 12.907±0.256. The corresponding log P value (1.114) indicates the relative polar nature of the DS at physiological pH and therefore, justifies the selection of CVI to enhance the transdermal delivery. The experimental value of log P was found to be close to the calculated value for DS at the physiological pH (23).

The pH solubility profile of DS indicates that the solubility of the drug increases with pH at values exceeding the pKa (pKa ~3.80) (Figure 1). The pH-pKa differential determines the fraction of ionized species and therefore the iontophoretic efficiency. Further, the majority of the soluble fraction of DS (~0.999) is likely to exist in an ionized state at the physiological pH as per equation [2] making DS a suitable candidate for cathodal iontophoresis. The diclofenac anion would be repelled away from the cathode by electrorepulsion, which acts as a primary driving force during CVI.

Figure 1: pH solubility profile of diclofenac sodium.Each data point represents mean±SD (n=3).

Figure 1:

pH solubility profile of diclofenac sodium.

Each data point represents mean±SD (n=3).

3.2 Gel preparation

Gels are known to be the most suited vehicles for iontophoresis as they can be easily integrated within the device (14). Bioadhesive gels are advantageous compared to liquids in that they adhere well to the skin conforming to the skin contours thereby preventing the material from flowing over the skin (24). Water was used as a solvent in the gels due to its biocompatibility, high dielectric constant and its ability to render the gels more conductive. Bearing in mind the low pKa value of DS, the gels were buffered to a pH of 7.40 so as to ensure that the major fraction of the drug existed in the ionized state. Moreover, the pH selected is less prone to cause skin irritation. Considering the permeation issues of DS, terpenes were used as a permeation enhancer in the hydrogels (Table 1). Terpenes are GRAS listed under natural transdermal penetration enhancers that are non-toxic and non-irritating (25). As the terpenes were insoluble in the aqueous phase, ethanol (40% w/w) was used as a co-solvent to facilitate its dissolution in the hydrogels. HEC is a nonionic polymer that is GRAS listed and approved by the USFDA for topical applications owing its nonirritating and nonsensitizing nature. HEC was used as a matrix due to its good bioadhesion, high polarity, biocompatibility and nonionic nature. Being non-ionic, HEC avoids the possible drug-polymer interaction and active ionic competition during CVI so that the iontophoretic transport of DS remains unaffected. HEC is used as a matrix material in the design of the Fentalis, a marketed transdermal iontophoretic patch of Fentanyl (26).

3.3 FTIR studies

The IR spectra of DS displayed distinctive peaks at 3380.20 cm-1, 1570.12 cm-1 and at 747.35 cm-1 due to the NH stretching of the secondary amine, -C=O stretching of the carboxylate ion and -C-Cl stretching, respectively. The spectra of HEC portrayed the -C-OH stretching peak at 3444 cm-1, while the SP3 stretching vibrations of -CH2 group were seen at 2923 cm-1 and 1020 cm-1. In the spectra of the gels, the characteristic peaks of diclofenac appeared at 1568.24 cm-1 (C=O, carboxylate) and at 744.56 cm-1 (-C=Cl, stretching) proving the chemical integrity of DS in hydrogels. The IR spectral observations rule out the possible interference in the iontophoretic transport due to chemical interaction.

3.4 Viscosity profiling

The viscosity profiles of the gels were found to overlap with each other indicating that the concentration of HEC in the gel is likely to determine the gel viscosity rather than the composition of the dispersion media (Figure 2). The observations were consistent with the earlier reports that suggest that viscosity of hydrogels were a function of HEC concentrations (27). The non-Newtonian nature of the gels was clearly evident as the viscosity was found to drop at high rates of shear. Gels of comparable viscosities have been used in the past for iontophoretic delivery of DS (28).

Figure 2: Rheograms representing the rapid viscosity profiles of hydrogels.

Figure 2:

Rheograms representing the rapid viscosity profiles of hydrogels.

Iontophoresis is likely to induce a slight change in the pH or temperature depending on the electrodes used, voltage applied and the nature of the permeant. Such changes in pH or temperature are likely to induce a potential change in the gel viscosity and therefore the drug delivery from a pH-sensitive or a thermo-sensitive polymer making them a poor choice for iontophoretic delivery. However, gels of HEC are less prone to viscosity changes due to minute shifts in the pH or temperature making them the materials of choice for iontophoretic delivery. HEC solutions undergo small changes in viscosity in the pH range of 2–12 while they exhibit greatest viscosity stability in the pH range of 6.5–8.0 (29).

3.5 Determination of conductivity

The conductivity of the control gel containing DS was found to be 384.4±1.20 μSi/cm that was significantly higher (p<0.0001) than the value obtained for the placebo gel (162.1±2.5 μSi/cm). The increase in conductivity on the addition of DS indicated the potential of the drug to ionize at pH 7.40. Further, since the conductivity of PB containing DS (398.4±5.48 μSi/cm) was comparable (p>0.05) to the value obtained for the control gel, it was obvious that the increase in gel viscosity failed to restrict the ionic mobility and therefore is unlikely to hamper the iontophoretic transport of DS. Solutions having similar conductivities have enabled iontophoretic transport of therapeutic agents (14, 24).

3.5.1 In vitro passive diffusion

The passive steady state flux of DS from PB and the control gel was found to be 0.099±0.011 and 0.102±0.012 μmol/cm2/h, respectively. Though the gel viscosity was higher compared to the aqueous solution, no significant difference (p>0.05) in the passive steady state flux of DS was evident for the control gel when compared to the solution. The comparable values of fluxes indicated that the gel viscosity did not substantially restrict the mobility of the diclofenac anion. These observations imply that diffusion of the drug through the skin was the rate determining step in the permeation of DS rather than the diffusion through the gel matrix. An earlier study has shown that diffusion of ionic permeants from gels were not different from aqueous solutions (11).

The enhancement with different penetration enhancer for DS was found to increase in the following order: geraniol>l-menthol>thymol. Of all the hydrogels, F1 emerged as the most efficacious formulation with an enhancement of ~2 fold compared to the passive control (Figure 3). Geraniol is an unsaturated acyclic monoterpene having a trans confirmation with two double bond. Generally, acyclic terpenes by virtue of the definitive hydrocarbon tail with a polar head are said to be structurally well suited to disrupt the stratum corneum lipids. Geraniol at a concentration of 1% in gels is reported to enhance the passive permeation of DS by 19-fold (30). The better efficacy of geraniol compared to l-menthol could be due to the fact that geraniol being a liquid terpene has a lesser tendency to form hydrogen bonds with the ceramides and cholesterol of the skin lipids compared to solid counterparts. Further, the average number of hydrogen bonds that could be formed by liquid and solid terpenes is reported to be 1.1 and 2.0, respectively (31). However, of the three terpenes, thymol was not as effective as other terpenes in accelerating the in vitro transport of DS.

Figure 3: In vitro passive and iontophoretic transport of diclofenac sodium.Each data point represents mean±SD (n=3), (***p<0.0001, *p<0.05), compared to passive control (FC).

Figure 3:

In vitro passive and iontophoretic transport of diclofenac sodium.

Each data point represents mean±SD (n=3), (***p<0.0001, *p<0.05), compared to passive control (FC).

3.5.2 In vitro iontophoretic permeation

The three pathways utilized by permeants to pass through the stratum corneum of the skin are transcellular, paracellular and follicular pathways. Of these, the paracellular lipid and follicular shunt pathways have been identified to be the key pathways involved in the iontophoretic transport of DS (9). Due to higher current intensities observed at higher voltages (3.0 V and 4.5 V) iontophoretic trials were carried out only at voltages of 1.5 V. Current strengths exceeding 0.5 mA/cm2 often cause skin irritation, skin damage or uncomfortable electrical stimulation during iontophoresis (32). CVI significantly increased (p<0.0001) the amount of DS permeated through the skin in 8 h, compared to their passive counterparts (Figure 3). Of all the hydrogels, F1 emerged as the leading formulation with an enhancement factor of 5.16 compared to the passive control. The better efficacy of terpenes can be attributed to the presence of hydroxyl groups which are known to strongly interact and disrupt the hydrogen bonds prevailing between ceramide head group of the stratum corneum under the applied electric filed (11). The target flux of DS deduced based on equation (4) was found to be 19 μmol/h. Considering the iontophoretic flux of the F1 (0.526±0.041 μmol/cm2/h) at 1.5 V, a patch having a dimension of 36 cm2 would be able to meet the target flux of DS.

3.6 In vivo pharmacodynamics

CVI following F1 treatment suppressed the carrageenan-induced edema as early as 1 h and completely inhibited the paw swelling for 8 h indicating a faster and long lasting action (Figure 4). Moreover, with F1, a significantly better inhibition (p<0.001) was seen with CVI compared to passive treatment of the same hydrogel at all time points. Likewise, on passive treatment the percentage inhibition by F1 at all the time points were significantly higher (p<0.05) compared to the control (FC). However, the effect of CVI was found to be more pronounced compared to the efficacy of geraniol alone. The in vivo studies conclusively demonstrated the superior efficacy of F1 in inhibiting the paw edema following the carrageenan challenge. Due to the bioadhesive nature, the gels were well retained till the end of the study maintaining excellent contact with the skin.

Figure 4: Percentage inhibition of paw thickness as a function of time.Each data represents mean±SEM (n=3), (***p<0.0001, *p<0.05), compared with passive control (FC).

Figure 4:

Percentage inhibition of paw thickness as a function of time.

Each data represents mean±SEM (n=3), (***p<0.0001, *p<0.05), compared with passive control (FC).

4 Conclusion

Hydrogels of DS were developed using GRAS listed penetration enhancers and matrix material. By virtue of the unique composition, the hydrogels developed are likely to be robust enough to resist viscosity changes despite minute changes in the pH or temperature so that the iontophoretic delivery would be unaffected. The in vitro studies indicated that the amount of DS delivered from hydrogels was comparable to those delivered from aqueous solutions. The in vivo studies suggested that the hydrogel F1 was able to safely deliver therapeutic amounts of DS by transdermal iontophoresis.


Corresponding author: S. Arunkumar, Department of Pharmaceutics, KLE University’s College of Pharmacy, Bengaluru, India, e-mail:

Acknowledgments

The authors are thankful to Ashland Chemicals Ltd, India for the gift sample of Natrosol 250 M.

References

1. Chopra A. Epidemiology of rheumatic musculoskeletal disorders in the developing world. Best Pract Res Cl Rh. 2008;22(4):583–604.10.1016/j.berh.2008.07.001Search in Google Scholar

2. Mehallo CJ, Drezner JA, Bytomski JR. Practical management: nonsteroidal anti inflammatory drug (NSAID) use in athletic injuries. Clin J Sport Med. 2006;16(2):170–4.10.1097/00042752-200603000-00015Search in Google Scholar

3. Lionberger DR, Brennan MJ. Topical nonsteroidal anti-inflammatory drugs for treatment of pain due to soft tissue injury: diclofenac epolamine topical patch. J Pain Res. 2010;3:223–33.Search in Google Scholar

4. Rosenstein ED. Topical agents in the treatment of rheumatic disorders. Rheum Dis Clin North Am. 1999;25:899–919.10.1016/S0889-857X(05)70109-5Search in Google Scholar

5. Kochhar C, Imanidis G. In vitro transdermal iontophoretic delivery of leuprolide-mechanisms under constant voltage application. J Pharm Sci. 2003;92(1):84–96.10.1002/jps.10257Search in Google Scholar PubMed

6. Riecke FB, Bartels ME, Pedersen ST, Madsen SR, Bliddal H, Samsoe BD, Nielsen LA. A microdialysis study of topically applied diclofenac to healthy humans: Passive versus iontophoretic delivery. Res Pharm Sci. 2011;1:76–9.10.1016/j.rinphs.2011.11.001Search in Google Scholar PubMed PubMed Central

7. Xin C, Wang L-h, Yue Y, Gao Y-n, Wang Q-f, Yang Y, Li S-m. A novel method to enhance the efficiency of drug transdermal iontophoresis delivery by using complexes of drug and ion-exchange fibers. Int J Pharm. 2012;428:68–75.10.1016/j.ijpharm.2012.02.039Search in Google Scholar PubMed

8. Kigasawa K, Kajimoto K, Watanabe M, Kanamura K, Saito A, Kogure K. In vivo transdermal delivery of diclofenac by ion exchange iontophoresis with geraniol. Biol Pharm Bull. 2009;32:684–7.10.1248/bpb.32.684Search in Google Scholar PubMed

9. Fang JY, Wang RJ, Huang YB, Wu PC, Tsai YH. Passive and iontophoretic delivery of three diclofenac salts across various skin types. Biol Pharm Bull. 2000;23(11):1357–62.10.1248/bpb.23.1357Search in Google Scholar PubMed

10. Sugibayashi K, Kagino M, Numajiri S, Inoue N, Kobayashi D, Kimura M, Yamaguchi, M, Morimoto Y. Synergistic effect of iontophoresis and jet injector pretreatment on the in vitro skin permeation of diclofenac and angiotensin II. J Pharm Pharmacol. 2000;52:1179–86.10.1211/0022357001777306Search in Google Scholar PubMed

11. Singh G, Ghosh B, Kaushalkumar D, Somsekhar V. Screening of venlafaxine hydrochloride for transdermal delivery: passive diffusion and iontophoresis. AAPS PharmSciTech 2008;9(3):1–7.10.1208/s12249-008-9111-3Search in Google Scholar PubMed PubMed Central

12. Tenambergen F, Maruiama CH, Mader K. Dual asymmetric centrifugation as an alternative preparation method for parentral fat emulsions in preformulation development. Int. J Pharm 2013;447(1–2):31–7.10.1016/j.ijpharm.2013.02.033Search in Google Scholar

13. Anton Paar MCR-302 series instruction manual, software version 3.62.2011. Anton Paar GmbH, Graz, Austria. Doc Number: C92IB001EN-C. http://www.anton-paar.com.Search in Google Scholar

14. Kotwal V, Bhise K, Thube R. Enhancement of iontophoretic transport of diphenhydramine hydrochloride thermosensitive gel by optimization of pH, polymer concentration, electrode design, and pulse rate. AAPS PharmSciTech. 2007;8(4):E1–6.10.1208/pt0804120Search in Google Scholar

15. Banga AK. Electrically assisted transdermal and topical drug delivery. Taylor and Francis: London, 1998;33–48.10.4324/9780203483985Search in Google Scholar

16. Ghosh B, Reddy LH. Effect of physicochemical parameters on skin permeability of antihypertensive. Ind J Exp Bio. 2001;39(7):710–4.Search in Google Scholar

17. Thummel KE, Shen DD, Isoherrannen N, Smith HE. In: Brunton, LL, Lazo JS, Parker KL, editors. Goodman and Gilman’s: the pharmacological basis of therapeutics, 11th ed. McGraw-Hill: New York, 2006.Search in Google Scholar

18. Kienzler JL, Gold M, Nollevaux F. Systemic bioavailability of topical diclofenac gel 1% versus oral diclofenac sodium in healthy volunteers. J Clin Pharmacol. 2010;50(1):50–61.10.1177/0091270009336234Search in Google Scholar

19. Emami, J, Ghassami N, Talari R. A rapid and sensitive modified HPLC method for determination of diclofenac in human plasma and its application in pharmacokinetic studies. DARU 2007;15:132–8.Search in Google Scholar

20. Varghese E, Khar RK. Enhanced skin permeation of diclofenac by iontophoresis: in vitro and in vivo studies. J Control Release. 1996;38:21–7.10.1016/0168-3659(95)00095-XSearch in Google Scholar

21. Babu NP, Pandikumar P, Ignacimuthu S. Lysosomal membrane stabilization and anti-inflammatory activity of clerodendrum phlomidis L.f, a traditional medicinal plant. J Eth Pharm. 2011;135:779–85.Search in Google Scholar

22. Singh P, Maibach HI. Iontophoresis: an alternative to the use of carriers in cutaneous drug delivery. Adv Drug Deliv Rev. 1996;18(3):379–94.10.1016/0169-409X(95)00082-ISearch in Google Scholar

23. Ghafourian T, Zandasrar P, Hamishekar H, Nokhodchi A. The effect of penetration enhancers on drug delivery through skin: A QSAR study. J Control Release. 2004;99(1):113–25.10.1016/j.jconrel.2004.06.010Search in Google Scholar PubMed

24. Djabri A, Guy RH, Delgado-Charro MB. Transdermal iontophoresis of ranitidine: an opportunity in paediatric drug therapy. Int J Pharm. 2012; 435(1):27–32.10.1016/j.ijpharm.2012.03.006Search in Google Scholar PubMed

25. Fox LT, Gerber M, Du Plessis J, Hamman JH. Transdermal drug delivery enhancement by compounds of natural origin. Molecules 2011;16:10507–10540.10.3390/molecules161210507Search in Google Scholar

26. Lane ME. The transdermal delivery of fentanyl. Eur. J Pharm Biopharm. 2011;84:49–55.Search in Google Scholar

27. Furst T, Piette M, Lechanteur A, Evrard B, Piel G. Mucoadhesive cellulosic derivative sponges as drug delivery system for vaginal application. Eur J Pharm Biopharm. 2015;1–8.10.1016/j.ejpb.2015.01.019Search in Google Scholar PubMed

28. Fang JY, Sung KC, Lin HH, Fang CL. Transdermal iontophoretic delivery of diclofenac sodium from various formulations: in vitro and in vivo studies. Int J Pharm. 1999;178:83–92.10.1016/S0378-5173(98)00361-5Search in Google Scholar

29. Natrosol hydroxyethyl cellulose. Physical and chemical properties, Ashland inc. http://www.ashland.com/Ashland/Static/.../AAFI/PRO-250-11G_Natrosol11G.pdf.Search in Google Scholar

30. Arellano A, Santoyo S, Martin C, Ygartua P. Enhancing effect of terpenes on the in vitro percutaneous absorption of diclofenac sodium. Int J Pharm. 1996;130(1):141–5.10.1016/0378-5173(95)04364-0Search in Google Scholar

31. Kang L, Yap CW, Lim PFC, Chen YZ, Ho PC, Chan YW, Wong GP, Chan SY. A Formulation development of transdermal dosage forms: QSAR model for predicting activities of terpenes that enhance drug penetration through human skin. J Control Release. 2007;120:211–9.10.1016/j.jconrel.2007.05.006Search in Google Scholar

32. Banga AK, Chien YW. Iontophoretic delivery of drugs: fundamentals, developments and biomedical applications. J Control Release. 1988;7:1–24.10.1016/0168-3659(88)90075-2Search in Google Scholar

Received: 2015-6-28
Accepted: 2015-9-1
Published Online: 2015-10-17
Published in Print: 2016-1-1

©2016 by De Gruyter

This article is distributed under the terms of the Creative Commons Attribution Non-Commercial License, which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.